Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study.

Islas-Andrade S, Revilla-Monsalve MC, Martínez de Hurtado E, Chacín LF, Caminos QR, Yupanqui H, López G, de la Torre W; Latin American Study Group.

Pharmacology. 2003 Jun;68(2):89-95.

PMID:
12711836
2.

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group.

Diabetes Care. 2004 Jun;27(6):1265-70.

PMID:
15161773
3.

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE.

Diabetes Care. 2001 Jun;24(6):983-8.

PMID:
11375357
4.

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group.

Diabetes Care. 2003 Jul;26(7):2063-8. Erratum in: Diabetes Care. 2003 Sep;26(9):2708.

PMID:
12832314
5.

Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.

Abrahamian H, Francesconi M, Loiskandl A, Dzien A, Prager R, Weitgasser R.

Diabetes Technol Ther. 2004 Feb;6(1):31-7.

PMID:
15000767
6.

[Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].

Li YX, Ding GX, Li QF, Chen L, Hu GL, Ji QH, Wang SJ, Guo Y, Luo R, Hou WK, Wang PN, Zhang NY, Zhang YP, Wang H.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2008 Apr;30(2):211-3. Chinese.

7.

Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.

Tentolouris N, Boutati E, Karambakalis N, Perrea D, Tselepis AD, Tsoukala C, Kyriaki D, Lourida E, Anastasopoulou I, Karafoullidou A, Raptis SA, Katsilambros N.

Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):6-12. Erratum in: Nutr Metab Cardiovasc Dis. 2006 Jan;16(1):81. Perea, D [corrected to Perrea, D].

PMID:
15871845
8.
10.

Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.

Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D.

J Clin Endocrinol Metab. 2002 Sep;87(9):4171-6.

PMID:
12213867
11.

Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.

Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR.

Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):484-90.

PMID:
12469362
12.

Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.

Diabetes Care. 2003 Jun;26(6):1685-90.

PMID:
12766094
13.

Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.

Voytovich MH, Haukereid C, Hjelmesaeth J, Hartmann A, Løvik A, Jenssen T.

Clin Transplant. 2007 Mar-Apr;21(2):246-51.

PMID:
17425753
14.

Postmarketing surveillance study of nateglinide in Japan.

Taki H, Maki T, Iso T, Iwamoto K, Kajiura T.

Adv Ther. 2005 Sep-Oct;22(5):513-26.

PMID:
16418160
15.

Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.

Hazama Y, Matsuhisa M, Ohtoshi K, Gorogawa S, Kato K, Kawamori D, Yoshiuchi K, Nakamura Y, Shiraiwa T, Kaneto H, Yamasaki Y, Hori M.

Diabetes Res Clin Pract. 2006 Mar;71(3):251-5. Epub 2005 Oct 7.

PMID:
16214255
16.

Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.

Israel MK, Istvan E, Baron MA.

Vasc Health Risk Manag. 2008;4(6):1167-78. Review.

17.

Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.

Schatz H, Schoppel K, Lehwalder D, Schandry R.

Exp Clin Endocrinol Diabetes. 2003 Aug;111(5):262-6.

PMID:
12951631
18.
19.

Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.

Rosenstock J, Shen SG, Gatlin MR, Foley JE.

Diabetes Care. 2002 Sep;25(9):1529-33.

PMID:
12196422
20.

Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China.

Gao X; Mitiglinide Versus Nateglinide Comparison Study Group.

J Int Med Res. 2009 May-Jun;37(3):812-21.

PMID:
19589264
Items per page

Supplemental Content

Write to the Help Desk